For the quarter ending 2025-12-31, UPXI made $8,052,040 in revenue. -$178,924,930 in net income. Net profit margin of -2222.11%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | 8,052,040 | 9,239,745 | 3,268,334.5* | 4,005,492 |
| Cost of revenue | 1,340,881 | 956,745 | 1,256,555.5* | 1,031,386 |
| Gross profit | 6,711,159 | 8,283,000 | 2,011,779* | 2,974,106 |
| Sales and marketing | 915,841 | 1,067,555 | 1,014,012* | 949,963 |
| Share-based compensation | - | - | - | 32,578 |
| Distribution costs | 924,201 | 887,596 | 593,743.5* | 1,276,422 |
| General and administrative | 5,522,786 | 9,257,208 | 8,896,951.75* | 1,548,590 |
| Unrealized loss on digital assets | -164,495,019 | - | - | - |
| Crypto asset, realized gain (loss), operating | -341,599 | - | - | - |
| Realized and unrealized (gain) loss on digital assets | - | - | 26,368.5* | - |
| Unrealized (gain) on digital assets | - | 77,996,124 | - | - |
| Stock-based compensation | 8,300,673 | 5,756,398 | 589,215.5* | - |
| Amortization of acquired intangible assets | 19,190 | 19,190 | 19,188* | 19,190 |
| Impairment on assets from manufacturing shut down | 1,422,289 | - | - | - |
| Depreciation | 134,388 | 135,902 | -9,700.5* | 220,562 |
| Impairment of long-lived asset - building | - | - | 0* | - |
| Loss on the sale / abandonment of assets in relocation | - | - | 0* | - |
| Impairment of intangible assets and goodwill | - | - | 0* | - |
| Lease impairment (gain on settlement), delray beach facility | - | - | -67,498.5* | - |
| Total operating expenses | 182,075,986 | -60,872,275 | 11,009,543.25* | 4,047,305 |
| Loss from operations | -175,364,827 | 69,155,275 | -8,997,764.25* | -1,073,199 |
| Interest expense, net | -3,604,709 | -2,699,383 | -489,381* | -228,111 |
| Other income, net | 44,606 | 292,230 | 193,266.75* | -228,111 |
| Other expense, net | -3,560,103 | -2,407,153 | -296,114.25* | - |
| Loss on operations before income tax | -178,924,930 | 66,748,122 | -9,293,878.5* | -1,301,310 |
| Income tax benefit (expense) | 0 | 0 | 0* | - |
| Net income (loss) from continuing operations | - | 66,748,122 | -9,293,878.5* | -1,301,310 |
| Interactive offers | - | - | 0* | - |
| Vitamedica | - | - | 0* | - |
| E-core | - | - | 0* | - |
| Gain (loss) from the sale of total | - | - | 0* | - |
| Interactive offers | - | - | 0* | - |
| Vitamedica | - | - | 0* | - |
| E-core | - | - | 0* | - |
| Income (loss) income from discontinued operations | - | - | 0* | - |
| Net loss | -178,924,930 | - | -9,293,878.5 | -1,301,310 |
| Basic EPS | -2.94 | 1.21 | -0.429 | -1.24 |
| Diluted EPS | - | 0.76 | -0.429 | -1.24 |
| Basic Average Shares | 60,829,603 | 55,340,634 | 21,651,946 | 1,045,429 |
| Diluted Average Shares | 60,829,603 | 88,479,950 | 21,651,946 | 1,045,429 |
UPEXI, INC. (UPXI)
UPEXI, INC. (UPXI)